Atara Biotherapeutics, Inc. Profile Avatar - Palmy Investing

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical…

Biotechnology
US, South San Francisco [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Atara Biotherapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Atara Biotherapeutics, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Atara Biotherapeutics, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of ATRA's Analysis
CIK: 1604464 CUSIP: 046513107 ISIN: US0465131078 LEI: - UEI: -
Secondary Listings
ATRA has no secondary listings inside our databases.